Research progress on NCOA4-mediated ferritinophagy and related diseases.
- Author:
Chen JIA
1
;
Hong-Ji LIN
2
;
Fang CUI
3
;
Rui LU
2
;
Yi-Ting ZHANG
4
;
Zhi-Qin PENG
5
;
Min SHI
1
Author Information
1. Department of Clinical Laboratory, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
2. College of Basic Medical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
3. Core Facilities and Centers, Hebei Medical University, Shijiazhuang 050017, China.
4. College of Medical Technology, Hebei Medical University, Shijiazhuang 050031, China.
5. Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050011, China.
- Publication Type:English Abstract
- MeSH:
Humans;
Nuclear Receptor Coactivators/physiology*;
Ferritins/metabolism*;
Animals;
Neurodegenerative Diseases/metabolism*;
Iron/metabolism*;
Autophagy/physiology*;
Liver Cirrhosis/metabolism*;
Carcinoma, Renal Cell/metabolism*;
Kidney Neoplasms/physiopathology*
- From:
Acta Physiologica Sinica
2025;77(1):194-208
- CountryChina
- Language:Chinese
-
Abstract:
Nuclear receptor co-activator 4 (NCOA4) acts as a selective cargo receptor that binds to ferritin, a cytoplasmic iron storage complex. By mediating ferritinophagy, NCOA4 regulates iron metabolism and releases free iron in the body, thus playing a crucial role in a variety of biological processes, including growth, development, and metabolism. Recent studies have shown that NCOA4-mediated ferritinophagy is closely associated with the occurrence and development of iron metabolism-related diseases, such as liver fibrosis, renal cell carcinoma, and neurodegenerative diseases. In addition, a number of clinical drugs have been identified to modulate NCOA4-mediated ferritinophagy, significantly affecting disease progression and treatment efficacy. This paper aims to review the current research progress on the role of NCOA4-mediated ferritinophagy in related diseases, in order to provide new ideas for targeted clinical therapy.
